Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Completed 5Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × L-BLP25 × Clear all
NCT02049151 2017-08-23

START2

EMD Serono

Phase 3 Terminated
35 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Merck KGaA, Darmstadt, Germany

Phase 3 Terminated
285 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡